UNIT 6-10, ZEUS BUILDING, DIDCOT, X0
Shareholder Meeting Held; Matters Submitted to Vote on May 20, 2026
Reports First Quarter 2026 Financial Results and Updates on Corporate Developments
Changes in Board, Management or Compensation
Departure of Officer - Gemma Jones Exits Barinthus Biotherapeutics
Material disclosure
Amendment to Merger Agreement with Barinthus Biotherapeutics
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus Filed Pursuant to Rule 425
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Definitive Merger Proxy Statement
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Initial Statement of Beneficial Ownership
Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
Definitive Revised Proxy Statement
SEC Staff Correspondence